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Ferroxidase (encoded by the mco gene), a component of a ferrous iron uptake pathway in Pseudomonas
aeruginosa, was detected in all of the 35 respiratory clinical isolates surveyed; in contrast, considerable
variation in siderophore expression was observed. The ubiquitous expression of this periplasmic ferroxidase
suggests that it plays a key role in iron uptake in this opportunistic pathogen.
Pseudomonas aeruginosa is the causative agent for a variety
of severe human infections and disease, including colonization
of the lungs of cystic fibrosis patients and infection of burns
and immunocompromised patients (8). This opportunistic
pathogen is found in a diverse range of ecological niches,
including soil, plants, and animal hosts. P. aeruginosa has
evolved a variety of iron acquisition mechanisms. Although it is
required at a physiological concentration of around 107 to
105 M in most bacteria, iron is not freely available in the
human host. In animals, iron is stored intracellularly as Fe(III)
in ferritin, while this ion is transported throughout the body by
using the Fe(III) binding proteins, such as transferrin. Iron
sequestration via transferrin and lactoferrin is of critical im-
portance in the prevention of iron acquisition by bacteria dur-
ing infection (21), and recently it was shown that lactoferrin
prevents establishment of P. aeruginosa biofilms by preventing
bacterial iron acquisition (15).
Faced with the lack of freely available iron, pathogenic bac-
teria have evolved a number of systems to extract iron from the
host (2, 21). Most research has focused on the production of
siderophores, low-molecular-weight molecules with a high af-
finity for Fe(III) that are capable of acquiring iron from the
host stores. In P. aeruginosa, two siderophores, pyochelin and
pyoverdin, have been characterized (19). Pyochelin is consid-
ered to play only a minor role during pathogenicity due to its
relatively low affinity for Fe(III) and the lack of virulence
deficiency of pyochelin mutants in animal model systems (4, 9,
17). Although experiments using the burnt mouse model sys-
tem have indicated that pyoverdin is essential for virulence of
P. aeruginosa (9), isolates lacking pyoverdin have been found in
infected cystic fibrosis patients (5). It has also been reported
that siderophore-deficient mutants are capable of establishing
infection in immunocompromised mice when inoculated both
intramuscularly and intranasally (17). These reports suggest
that P. aeruginosa possesses additional iron uptake mecha-
nisms that have a role in pathogenesis.
Recently, we identified an Fe(II) iron acquisition pathway of
P. aeruginosa that is dependent on a periplasmic multicopper
oxidase (MCO) and independent of siderophores. This enzyme
acts as a ferroxidase, converting Fe(II) to Fe(III) (7). In the
host, this may occur after reductive release of iron from trans-
ferrin by leukopyocyanin (3). In this paper, we report the
examination of 35 isolates of P. aeruginosa with defined clinical
outcomes for the presence of the MCO protein and sidero-
phores.
Respiratory clinical isolates of P. aeruginosa, Pse 1 to Pse 41,
previously assembled by Hauser and coworkers from ventila-
tor-associated pneumonia patients with a variety of clinical
outcomes from death-related to complete recovery, were used
to conduct the investigation (6). Control strains used for the
experiments included P. aeruginosa PAO1 and PAK, sidero-
phore-deficient mutants generated by Ankenbauer and co-
workers (IA613, IA602, IA629, and IA635) (1), and an mco Tcr
mutant strain (7).
The clinical isolates and control strains were examined for
the production of pyoverdin and pyocyanin by using King B
and King A media, respectively. Quantitation of siderophores
was also carried out with the chrome azurol S (CAS) reagent in
a spectrophotometric assay (14). The total data collected from
the isolates are shown in Table 1. King A and King B solid
media were streaked from Luria-Bertani plate cultures of the
isolates and incubated overnight at 37°C. The CAS assay was
conducted from cell supernatants of the cultures grown for
24 h in CPS medium. CPS medium was prepared with 0.8%
Casamino Acids, 5 mM K2SO4, 5 mM K2HPO4, and 5 mM
KH2PO4. The solution was autoclaved prior to the addition of
MgSO4 to a final concentration of 1 mM. Supernatants were
obtained by centrifugation at 4,000  g for 10 min, and each
isolate was examined in triplicate. Supernatants were incu-
bated with the Fe(III)-loaded CAS reagent for 30 min prior to
spectrophotometric determination of the CAS-Fe(III) com-
plex remaining. Medium-only controls were included in the
experiment.
Pyoverdin production is shown in Table 1. In a qualitative
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test using King B medium to screen for pyoverdin production
under iron-limited conditions, production of pyoverdin ap-
peared to be absent in four of the clinical isolates, one of which
was associated with death of the human host. Quantitation of
siderophore production using the CAS reagent showed that its
level was highly variable in the death-related clinical isolates
(Pse 1 to Pse 10) (Fig. 1). In fact, the death-associated isolate
Pse 17 had one of the lowest levels of siderophore activity
detected in this collection of isolates. Similarly, some of the
isolates (Pse 35 and Pse 39), which had low 50% lethal doses
(LD50s) as reported by Schulert and coworkers (13) indicating
strong virulence in the animal model, had low levels of sidero-
phore activity (Table 1). Taken together, the results show that
siderophore production in strains of pathogenic P. aeruginosa
is highly variable. This is consistent with previous observations
of De Vos et al. (5), who examined isolates of P. aeruginosa but
did not report clinical outcomes associated with strains.
P. aeruginosa has also been shown to acquire iron from
human transferrin in vitro by two distinct mechanisms (3). In
addition to the siderophore-dependent removal of Fe(III)
from transferrin, it was observed that iron could be mobilized
by the redox active phenazine dye, pyocyanin. Reduction of
Fe(III) to Fe(II) by leukopyocyanin generates a soluble form
of iron that is not bound tightly by transferrin. It was shown by
Cox (3) that P. aeruginosa was capable of taking up Fe(II)
mobilized by pyocyanin. Recently, we showed that the MCO of
P. aeruginosa was important for Fe(II) acquisition under aero-
bic conditions and hypothesized that it acted as a ferroxidase in
a pathway whose existence was first established by Cox (3) The
clinical isolates were screened for the presence of the MCO via
Western blotting, using the polyclonal sera previously de-
scribed in reference 7. The MCO protein was detected in all of
the clinical isolates examined during this study (Fig. 2 and
Table 1). Given the presence of this protein in all of the clinical
isolates examined, we suggest that this iron uptake mechanism
may also play an important function during pathogenicity of
P. aeruginosa.
The acquisition of iron in the host environment by P. aerugi-
nosa has been largely attributed to the siderophore pyoverdin
(19, 20). However, the organism is known to possess a number
of other important mechanisms, including heme uptake (11)
FIG. 1. Quantitative determination of siderophore production by the clinical isolates. The removal of iron from the CAS reagent by the
supernatants of each isolate is expressed by 1/[CAS-FE] on the y axis. 1/[CAS-FE] is the inverse of the remaining reagent with Fe(III) bound, which
was determined by the spectrophotometric method, and the molar concentration of CAS-FE was calculated by using the molar extinction
coefficient as previously described by Schwyn and Neilands (14). The horizontal line represents the baseline as determined by medium-only
controls. The error bars represent 1 standard deviation.
FIG. 2. Western blot of selected isolates. The figure shows Western
blots of total soluble extracts, using polycolonal sera to the MCO (7)
(total protein concentration of 1 mg/ml). Lanes in blot 1: 1, Benchmark
(Invitrogen); 2, Pse 1; 3, Pse 5; 4, Pse 12; 5, Pse 17; 6, Pse 25; 7, Pse 39;
8, mco Tcr mutant; 9, PAK. Lanes in blot 2: 10, Pse 41; 11, IA613; 12,
PAO1; 13, mco Tcr mutant; 14, PAK. The arrowhead indicates the
position of the 65.8-kDa molecular mass marker. The marker apparent
molecular masses are 179.3, 120, 83.8, 65.8, 50.1, 38.6, 27.5, 20.5, 16.1,
and 6.7 kDa.
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and degradation and scavenging of iron from host sources such
as transferrin (3), and a putative ferrous iron transporter en-
coded by feoB can be found in the genome sequence (16).
There have been some suggestions that the acquisition of
heme, for which two separate mechanisms can be found in
P. aeruginosa, may compensate in the siderophore-deficient
strains (11, 17). The FeoB ferrous iron uptake protein of Le-
gionella pneumophila has been recently reported be important
for intracellular infections (12). Similarly, the FeoB protein of
Salmonella enterica serovar Typhimurium was also shown to be
important during colonization of the intestine of mice (18).
The uptake of Fe(II) under aerobic conditions during patho-
genicity via a combination of redox molecules and a ferroxi-
dase-dependent iron uptake system (10) appears to be an
emerging and important area of bacterial iron acquisition. The
identification of this novel MCO-dependent ferrous iron ac-
quisition system in P. aeruginosa and its presence in all exam-
ined clinical isolates, despite highly varied siderophore levels,
strongly indicate a likely function for this system during patho-
genicity. Furthermore, the presence of homologous putative
MCOs in many of the other gram-negative pathogen genomes
(7) suggests that ferroxidase-dependent iron uptake systems
may be of widespread importance.
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